Screener
R&D at other companies
Other financials
Where this comes from
Reported directly by Nuvation Bio in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The source filing: Nuvation Bio’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 6:55 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-336646
| Line item | For the Three Months Ended June 30, 2026 | For the Three Months Ended June 30, 2025 | For the Six Months Ended June 30, 2026 | For the Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Costs and expenses: | ||||
| Cost of sales | 911 | 172 | 1,286 | 172 |
| Cost of collaboration and license agreements revenue | 8,560 | 2,404 | 14,176 | 4,498 |
| Research and development | 30,661 | 27,362 | 65,708 | 51,963 |
| Selling, general and administrative | 42,591 | 38,484 | 80,900 | 73,877 |
| Total costs and expenses | 82,723 | 68,422 | 162,070 | 130,510 |
| Loss from operations | (51,036) | (63,589) | (47,155) | (122,593) |
| Other income (expense): |
Item 1. Financial Statements.
FAQ
- What is Nuvation Bio's R&D?
- Nuvation Bio (NUVB) reported R&D of $30.66M in Q2 2026.
- How has Nuvation Bio's R&D changed year-over-year?
- Nuvation Bio's R&D increased by 12.1% year-over-year, from $27.36M to $30.66M.
- What is the long-term trend for Nuvation Bio's R&D?
- Over 4 years (2021 to 2025), Nuvation Bio's R&D has grown at a 13.6% compound annual growth rate (CAGR), from $69.04M to $115.11M.
- What does R&D mean?
- Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.
Ask your AI about Nuvation Bio's r&d.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude